quinta-feira, 29 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleSeeking Alpha· July 21, 2026

Genuine Parts outlines 2026 adjusted EPS of $7.50-$8.00 while targeting separation in Q1 2027

View original at seekingalpha.com

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • GPC anticipates hosting Investor Days for both companies in early December in New York

    60% confidence
  • Of the $16 million Iran-related EBITDA impact in Q2, all but $1 million belonged to Automotive

    60% confidence
  • Independent owners represent a material opportunity, supported by new data analytics tools quartiling owners into 4 groups

    60% confidence
  • $210 million to $230 million of corporate costs are estimated to be allocated to Global Automotive

    60% confidence
  • Year-to-date restructuring costs of $134 million with $55 million realized savings, including ~$30 million in Q2 (a $0.16 per share benefit)

    60% confidence
  • GPC's outlook assumes market growth will be roughly flat

    60% confidence
  • Motion's project-based demand was the strongest since Q1 2023

    60% confidence
  • GPC is reaffirming its 2026 adjusted EPS guidance while updating other outlook elements

    60% confidence
  • U.S. health care expenses are up approximately 15%, while freight and rent expenses are up mid-single digits

    60% confidence
  • GPC is not currently in discussions with any competitor

    60% confidence
  • The financing fees under review relate to GPC's AR factoring program, which could stay or become a different instrument

    60% confidence
  • Investors should be careful not to over-index on monthly sequencing; July started in line with expectations

    60% confidence
  • GPC is taking a more prudent view of the second half for Global Automotive

    60% confidence
  • GPC expects adjusted diluted EPS of $7.50 to $8, up 5% at midpoint versus 2025

    60% confidence
  • Adjusted SG&A as a percentage of sales in Q2 was 29.1%

    60% confidence
  • In 2025, GPC's corporate costs were approximately $360 million

    60% confidence
  • GPC invested $205 million in capital expenditures year-to-date

    60% confidence
  • GPC finished Q2 with an estimated $16 million negative impact to EBITDA from the Iran conflict

    60% confidence
  • North America Auto comparable sales to retail customers decreased approximately 3%

    60% confidence
  • GPC feels good about its UK and Germany share position, with UK supply chain investments starting to bear fruit

    60% confidence
  • GPC will continue refining separation-related cost and dis-synergy estimates

    60% confidence
  • Pro forma Global Automotive business is expected to incur an additional $250 million of costs

    60% confidence
  • GPC continues to expect total GPC sales growth of 3% to 5.5%

    60% confidence
  • Adjusted gross margin expanded 20 basis points

    60% confidence
  • In Q1, GPC said it did not experience a material impact to financial results from the Iran conflict

    60% confidence
  • Global Automotive is estimated to face $25 million to $40 million of dis-synergies

    60% confidence
  • In Q1, separation work was described as on track

    60% confidence
  • National account growth reflects both market growth and share gains, aided by new leadership and analytics work

    60% confidence
  • GPC remains committed to maximizing shareholder value and will evaluate all potential options

    60% confidence
  • Total GPC sales were $6.5 billion in Q2

    60% confidence

Citado nestas reportagens da Via News

O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,994
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,994 factos verificados com a fonte5,503 documentos-fonte arquivados
Consulte estes dados → isubstrate.com